Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
24 jan 2007 - 08:14
Statutaire naam
Crucell N.V.
Titel
Crucell awarded EU grant to develop malaria vaccine
Bericht
Leiden, The Netherlands, January 24, 2007 – Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that it had received a European Union-funded grant aimed at advancing the development of a malaria vaccine. The €2.4 million grant, which was awarded to a Crucell-led consortium of six leading European Universities and companies in the field of malaria research, will finance pre-clinical studies toward an affordable, safe and efficacious two-component pediatric malaria vaccine.
“We are grateful to the EU for its decision to give us this grant,” said Dr. Jaap Goudsmit, Crucell’s Chief Scientific Officer. “The grant is important to our efforts to develop a malaria vaccine.” Dr. Goudsmit added: “The grant will go a long way toward streamlining Crucell’s focus on the fundamental global needs for a much-needed malaria vaccine.”
Datum laatste update: 01 september 2024